MEI Pharma, Inc. – NASDAQ:MEIP
MEI Pharma stock price today
$4.6
+2.15
+88.52%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market open
Closed in about 6 hours
MEI Pharma stock price monthly change
-15.86%
month
MEI Pharma stock price quarterly change
-15.86%
quarter
MEI Pharma stock price yearly change
-59.40%
year
MEI Pharma key metrics
Market Cap | 16.65M |
Enterprise value | 28.62M |
P/E | 0.73 |
EV/Sales | 0.42 |
EV/EBITDA | 1.25 |
Price/Sales | 0.28 |
Price/Book | 0.37 |
PEG ratio | 0.01 |
EPS | -7.49 |
Revenue | N/A |
EBITDA | -53.06M |
Income | -49.91M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 39.18% |
Oper. margin | 33.62% |
Gross margin | 98.36% |
EBIT margin | 33.62% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMEI Pharma stock price history
MEI Pharma stock forecast
MEI Pharma financial statements
| Jun 2022 | 11.41M | -16.26M | -142.54% |
|---|---|---|---|
| Mar 2023 | 5.89M | -14.48M | -245.76% |
| Jun 2023 | 1.45M | -10.02M | -688.33% |
| Mar 2024 | 0 | -9.12M |
| 2028 | 25M | -10.39M | -41.58% |
|---|
Analysts Price target
Financials & Ratios estimates
60.34%
Yield TTM
| Payout ratio | 0% |
|---|
| 2020 | |
|---|---|
| 2021 | |
| 2022 | |
| 2023 | |
| 2024 | 61.4% |
| Dec 2022 | 147599000 | 99.22M | 67.23% |
|---|---|---|---|
| Mar 2023 | 134187000 | 99.83M | 74.4% |
| Jun 2023 | 120809000 | 96.18M | 79.62% |
| Mar 2024 | 71260000 | 20.23M | 28.39% |
| Jun 2022 | -15.50M | 20.11M | 20K |
|---|---|---|---|
| Mar 2023 | -12.13M | 10.02M | 0 |
| Jun 2023 | -11.30M | 19.39M | 0 |
| Mar 2024 | -2.92M | 122K | 0 |
MEI Pharma alternative data
| Aug 2023 | 102 |
|---|---|
| Sep 2023 | 102 |
| Oct 2023 | 46 |
| Nov 2023 | 46 |
| Dec 2023 | 46 |
| Jan 2024 | 46 |
| Feb 2024 | 46 |
| Mar 2024 | 46 |
| Apr 2024 | 46 |
| May 2024 | 46 |
| Jun 2024 | 46 |
| Jul 2024 | 46 |
MEI Pharma other data
44.01%
-34.28%
of MEIP is owned by hedge funds
88
-17
56.40M
-32.78M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2023 | 81500 | 0 |
| Sep 2023 | 336100 | 15000 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | ANSON FUNDS MANAGEMENT LP 10 percent owner | Common Stock | 48,060 | $6.85 | $329,355 | ||
Sale | ANSON FUNDS MANAGEMENT LP 10 percent owner | Put Option (obligation to buy) | 9,000 | $7 | $63,000 | ||
Sale | FUNICULAR FUNDS, LP 10 percent owner | Put Option (obligation to buy) | 6,000 | $7 | $42,000 | ||
Purchase | FUNICULAR FUNDS, LP 10 percent owner | Common Stock | 32,040 | $6.85 | $219,570 | ||
Purchase | ANSON FUNDS MANAGEMENT LP 10 percent owner | Common Stock | 33,600 | $6.46 | $217,123 | ||
Purchase | FUNICULAR FUNDS, LP 10 percent owner | Common Stock | 22,400 | $6.46 | $144,749 | ||
Purchase | ANSON FUNDS MANAGEMENT LP 10 percent owner | Common Stock | 120,000 | $6.01 | $721,080 | ||
Purchase | FUNICULAR FUNDS, LP 10 percent owner | Common Stock | 80,000 | $6.01 | $480,720 | ||
Purchase | BALTIC CHARLES V. III director | Common Stock | 81,500 | $0.23 | $18,338 | ||
Option | GOLD DANIEL P PHD director, officer.. | Common Stock | 5,000 | $2.52 | $12,600 |
| Quarter | Transcript |
|---|---|
| Q4 2023 26 Sep 2023 | Q4 2023 Earnings Call Transcript |
| Q4 2022 8 Sep 2022 | Q4 2022 Earnings Call Transcript |
| Q4 2021 2 Sep 2021 | Q4 2021 Earnings Call Transcript |
| Q4 2020 10 Sep 2020 | Q4 2020 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Daniel P. Gold (1954) Pres, Chief Executive Officer & Director | $1,030,000 |
Mr. David M. Urso B.A., Esq., J.D. (1964) Chief Operating Officer & Gen. Counsel | $680,470 |
| Dr. Richard G. Ghalie (1958) Chief Medical Officer | $550,550 |
| Dr. Robert D. Mass (1954) Strategic Advisor | $201,680 |
-
What's the price of MEI Pharma stock today?
One share of MEI Pharma stock can currently be purchased for approximately $4.6.
-
When is MEI Pharma's next earnings date?
Unfortunately, MEI Pharma's (MEIP) next earnings date is currently unknown.
-
Does MEI Pharma pay dividends?
Yes, MEI Pharma pays dividends and its trailing 12-month yield is 60.34% with 0% payout ratio. The last MEI Pharma stock dividend of undefined was paid on 24 Sep 2025.
-
How much money does MEI Pharma make?
MEI Pharma has a market capitalization of 16.65M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 33.76% to 65.3M US dollars.
-
What is MEI Pharma's stock symbol?
MEI Pharma, Inc. is traded on the NASDAQ under the ticker symbol "MEIP".
-
What is MEI Pharma's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of MEI Pharma?
Shares of MEI Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are MEI Pharma's key executives?
MEI Pharma's management team includes the following people:
- Dr. Daniel P. Gold Pres, Chief Executive Officer & Director(age: 71, pay: $1,030,000)
- Mr. David M. Urso B.A., Esq., J.D. Chief Operating Officer & Gen. Counsel(age: 61, pay: $680,470)
- Dr. Richard G. Ghalie Chief Medical Officer(age: 67, pay: $550,550)
- Dr. Robert D. Mass Strategic Advisor(age: 71, pay: $201,680)
-
How many employees does MEI Pharma have?
As Jul 2024, MEI Pharma employs 46 workers.
-
When MEI Pharma went public?
MEI Pharma, Inc. is publicly traded company for more then 21 years since IPO on 18 Dec 2003.
-
What is MEI Pharma's official website?
The official website for MEI Pharma is meipharma.com.
-
Where are MEI Pharma's headquarters?
MEI Pharma is headquartered at 11455 El Camino Real, San Diego, CA.
-
How can i contact MEI Pharma?
MEI Pharma's mailing address is 11455 El Camino Real, San Diego, CA and company can be reached via phone at 858 369 7100.
MEI Pharma company profile:
MEI Pharma, Inc.
meipharma.comExchange:
NASDAQ
Full time employees:
28
Industry:
Biotechnology
Sector:
Healthcare
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
11455 El Camino Real
San Diego, CA 92130
San Diego, CA 92130
CIK: 0001262104
ISIN: US55279B3015
CUSIP: 55279B202
